Search Results 21-30 of 78 for ☆보증업체 【위너보증.com / 가입코드 9122】 위너 ☆

  1. https://www.mayoclinic.org/organization_concepts.xml

  2. A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer - Mayo Clinic

    This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 ...

  3. Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  4. Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER - Mayo Clinic

    About this study. This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who ...

  5. ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency - Mayo Clinic

    The purpose of this study (Study INZ701-304 [ADAPT])) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who ...

  6. Px Code,Supply #,Description,Unit Price 278000026,3643,KIT HEMODIALYSIS CATHETER POLYURETHANE DUAL LUMEN OVER THE WIRE SYMMETRIC TIP 14.5FRX19CM,498.12 ...

  7. A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence - Mayo Clinic

    A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated ...

  8. A Study to Investigate the Safety and Effectiveness of FE 999049 in Controlled Ovarian Stimulation in Women Aged 35-42 Years Old - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  9. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung ...

  10. A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease - Mayo Clinic

    The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these ...